Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa
Open Access
- 19 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7), e69288
- https://doi.org/10.1371/journal.pone.0069288
Abstract
Cryptococcal meningitis (CM)-related mortality may be prevented by screening patients for sub-clinical cryptococcal antigenaemia (CRAG) at antiretroviral-therapy (ART) initiation and pre-emptively treating those testing positive. Prior to programmatic implementation in South Africa we performed a cost-effectiveness analysis of alternative preventive strategies for CM. Cost-effectiveness analysis. Using South African data we modelled the cost-effectiveness of four strategies for patients with CD4 cell-counts <100 cells/µl starting ART 1) no screening or prophylaxis (standard of care), 2) universal primary fluconazole prophylaxis, 3) CRAG screening with fluconazole treatment if antigen-positive, 4) CRAG screening with lumbar puncture if antigen-positive and either amphotericin-B for those with CNS disease or fluconazole for those without. Analysis was limited to the first year of ART. The least costly strategy was CRAG screening followed by high-dose fluconazole treatment of all CRAG-positive individuals. This strategy dominated the standard of care at CRAG prevalence ≥0.6%. Although CRAG screening followed by lumbar puncture in all antigen-positive individuals was the most effective strategy clinically, the incremental benefit of LPs and amphotericin therapy for those with CNS disease was small and additional costs were large (US$158 versus US$51per person year; incremental cost effectiveness ratio(ICER) US$889,267 per life year gained). Both CRAG screening strategies are less costly and more clinically effective than current practice. Primary prophylaxis is more effective than current practice, but relatively cost-ineffective (ICER US$20,495). CRAG screening would be a cost-effective strategy to prevent CM-related mortality among patients initiating ART in South Africa. These findings provide further justification for programmatic implementation of CRAG screening.Keywords
This publication has 52 references indexed in Scilit:
- Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitisAIDS, 2012
- Evaluation of a Novel Point-of-Care Cryptococcal Antigen Test on Serum, Plasma, and Urine From Patients With HIV-Associated Cryptococcal MeningitisClinical Infectious Diseases, 2011
- Cost‐Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV‐Infected Persons with a CD4+Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource‐Limited SettingsClinical Infectious Diseases, 2010
- Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South AfricaJournal of Infection, 2010
- Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programmeAIDS, 2010
- Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected casesBMC Infectious Diseases, 2010
- Treatment of Cryptococcal Meningitis in KwaZulu-Natal, South AfricaPLOS ONE, 2010
- Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South AfricaClinical Infectious Diseases, 2009
- Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2008
- Healthcare utilization of patients accessing an African national treatment programBMC Health Services Research, 2007